Maxcyte (MXCT) Net Equity Issued and Repurchased (2021)
Maxcyte's (MXCT) quarterly Net Equity Issued and Repurchased came in at -$184.3 million in Q4 2021, down 200.0% on a QoQ basis from $184.3 million in Q3 2021.
Maxcyte (MXCT) Net Equity Issued and Repurchased (2021) Analysis & Trends
Maxcyte (MXCT) has 1 years of Net Equity Issued and Repurchased data on file, last reported at -$184.3 million in Q4 2021.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$184.3 million in Q4 2021; TTM through Dec 2021 was $51.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $51.8 million, up 81.36% from the prior year.
- Net Equity Issued and Repurchased for Q4 2021 stood at -$184.3 million, down from $184.3 million in the prior quarter.
- Over the last five years, Net Equity Issued and Repurchased for MXCT reached as high as $184.3 million in Q3 2021 and fell as low as -$184.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 12.70 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Maxcyte | 110.62 Mn | 110.62 Mn | 8.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -184.27 Mn |
| Dec 31, 2021 | -184.27 Mn |
| Sep 30, 2021 | 184.27 Mn |
| Sep 30, 2021 | 184.27 Mn |
| Mar 31, 2021 | 51.81 Mn |
| Mar 31, 2021 | 51.81 Mn |